Reviving Early Diagnosis of Cardiovascular Disease in the Utrecht Health Project
Launched by UMC UTRECHT · Mar 7, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 50-80 years
- • Being a participant of LRGP
- • Having indicated in the LRGP informed consent to be interested in participating in further research.
- Exclusion Criteria:
- • Diagnosed with coronary artery disease and atrial fibrillation and heart failure.
- • Undergoing major (cardiovascular) surgery, and/or revascularisation therapy and/or transplantation treatment within 3 months after enrolment.
- • Not willing to give written informed consent for RED-LRGP.
- • Not allowing incidental findings to be reported to him/herself or their own GP.
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Utrecht, , Netherlands
Patients applied
Trial Officials
Monika Hollander, MD PhD
Principal Investigator
UMC Utrecht
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials